According to an announcement on the Canadian government's official website on August 22nd, Canadian Health Minister Mark Holland has introduced new measures regarding Nicotine Replacement Therapy (NRT) products in order to address the harm they pose to young people and to ensure that these products are only used by adults looking to quit smoking.
The new measures include:
- Prohibit advertising or promotion, including labels and packaging that may appeal to teenagers;
- Require new and emerging forms of nicotine replacement therapy (NRTs), such as nicotine pouches, to be sold only by pharmacists or individuals under pharmacist supervision, and must be placed behind the pharmacy counter;
- Ban the sale of emerging forms of nicotine replacement therapy, such as nicotine pouches, in flavors other than mint or menthol;
- Require nicotine addiction warnings to be prominently displayed on the packaging and clearly indicate its use as a smoking cessation aid for adults trying to quit smoking;
- Mandate manufacturers to submit samples of all new or revised nicotine replacement therapy license labels and packaging to ensure they do not appeal to teenagers.
According to Canada's Food and Drugs Act, NRT falls under the regulation of pharmaceutical products. All NRT products must obtain approval from Health Canada and be accompanied by an approved health claim in order to be legally sold in Canada.
The minister stated that...
Our primary goal is to protect the health and safety of Canadians, especially young Canadians. We know that smoking cessation products play an important role in helping adults quit smoking, but we need to ensure that these products are able to fulfill their intended purpose. Our action today is aimed at achieving this, while also protecting youth and non-smokers from the harmful effects of nicotine.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
![[2Firsts Special Report] EPO Enlarged Board of Appeal Issues Key Decision: China YTI Gains Procedural Advantage in Heated Tobacco Patent Dispute with Philip Morris](https://static.2firsts.com/uploads/20250619/680a1f4818d125725c6608db46873b7a.png?x-oss-process=style/origin)
